Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M

INTEGRATED BIOPHARMA INC

Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).
FY2023 revenue $50.7M (-9.8%); operating income $120K vs $2.7M; net loss $34K ($0.00 EPS).
Diluted EPS $0.00 for both Q4 and FY; prior year $0.05 and $0.12 respectively.
Contract Manufacturing Segment contributed 95% of total revenue; two largest customers accounted for ~89%.
Warehousing/distribution business segment grew slightly as a percentage of total revenue.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

INTEGRATED BIOPHARMA INC reported fiscal year ended June 30, 2023 results: revenue $50.7 million, net income a net loss of approximately $34,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.

Period: fiscal year ended June 30, 2023
Revenue: $50.7 million
Net income: a net loss of approximately $34,000 or $0.00 per share of common stock
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Revenues for the fiscal year ended June 30, 2023 were $50.7 million compared to $56.2 million for the fiscal year ended June 30, 2022, a decrease of $5.5 million or 9.8%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

INTEGRATED BIOPHARMA INC reported quarter ended June 30, 2023 results: revenue $13.0 million, net income approximately $40,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.

Period: quarter ended June 30, 2023
Revenue: $13.0 million
Net income: approximately $40,000 or $0.00 per share of common stock
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Revenue for the quarter ended June 30, 2023 was $13.0 million compared to $13.3 million for the quarter ended June 30, 2022, a decrease of $0.3 million or 2.3%.

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-23-026058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.